New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:08 EDTABT, ALR, DHR, RHHBYAlere CEO departure sharpens focus on potential acquisition, says JMP Securities
After the CEO of Alere, Ron Zwanziger, resigned, JMP Securities thinks the resignation "brings the notion of Alere's potential acquisition front and center." The firm sees Alere as "a natural fit" for Roche (RHHBY), Abbott (ABT), or Danaher (DHR).
News For ALR;RHHBY;DHR;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 5, 2015
13:58 EDTRHHBYSome European stocks still look appealing amid Greek uncertainty, Barron's says
Subscribe for More Information
July 1, 2015
08:46 EDTRHHBYExelixis says FDA extends PDUFA action date for cobimetinib NDA
Subscribe for More Information
June 30, 2015
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 26, 2015
16:00 EDTDHROptions Update; June 26, 2015
Subscribe for More Information
12:32 EDTDHRDanaher July options active
Subscribe for More Information
10:04 EDTDHR:High option volume stocks
Subscribe for More Information
June 25, 2015
16:50 EDTDHRDanaher amends, extends split-off exchange offer with NetScout
Danaher (DHR) announced that it has amended and extended by one business day its offer to exchange all outstanding common units of Potomac Holding LLC, a Danaher subsidiary formed to hold Danaher's Communications business, for outstanding shares of Danaher common stock that are validly tendered and not validly withdrawn. The split-off transaction is in connection with the previously announced combination of Danaher's Communications business with NetScout Systems (NTCT). Danaher is amending the offer by: increasing the upper limit on the exchange ratio to 2.4000 Potomac Holding LLC common units per share of Danaher common stock tendered from 2.2522 Potomac Holding LLC common units per share of Danaher common stock tendered; however, the final exchange ratio may be less than the upper limit; extending the Exchange Offer's expiration to 12:00 midnight, New York City time, on July 9, unless extended or terminated, from July 8; and amending the current expected three-day period over which the final exchange ratio will be determined to July 7, 8 and 9, (which previously was expected to be July 6, 7 and 8). The final exchange ratio will be announced by press release by 4:30 p.m., New York City time, on the expiration date. As of June 24, approximately 38,458 shares of Danaher common stock have been tendered.
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
12:52 EDTABTEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
11:41 EDTDHRNetScout shareholders approve proposal to acquire Danaher business
Subscribe for More Information
June 24, 2015
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
June 23, 2015
10:00 EDTALROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:13 EDTALRAlere upgraded to Buy from Neutral at Goldman
Goldman upgraded Alere to Buy and increased its price target to $60 from $50. The firm believes management's focus on improving the cost structure and potential for improved execution is underappreciated. Goldman sees margin leverage driven by new product launches, manufacturing and sourcing initiatives, and slowing regulatory headwinds. Further, potential divestitures of non-core assets will continue to de-leverage the balance sheet.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use